RESEARCH DIGEST / HUMAN RCTs · WHAT MOVED vs WHAT'S MIXED
NAD+ Benefits in Human Clinical Trials: What the Studies Actually Measured
Blood NAD+ goes up — that part is RCT-confirmed across NMN and NR. Functional outcomes are mixed. Hard clinical endpoints are still preliminary. Here is the split, study by study.
Start here
If you want one honest summary of the NAD+ benefits in human clinical trials, it is this: the building blocks reliably raise NAD+ in your blood, and almost nothing past that is settled. Randomized trials of NMN and NR (precursors — building blocks the body converts into NAD+) consistently push whole-blood NAD+ upward, sometimes more than doubling it [4]. But "more NAD+ in blood" is a lab number, not a life outcome. Whether that turns into more strength, longer life or fewer diseases is where the evidence gets thin and the reviews get cautious. This page keeps the two apart on purpose.
Nicotinamide Riboside (NR), the Most-Studied Oral Precursor
Nicotinamide riboside (NR) is the most clinically studied oral NAD+ booster, and its dose-response is the cleanest result in the field. In a randomized, double-blind, placebo-controlled trial in healthy overweight adults, NR at 100, 300 and 1000 mg/day for 8 weeks raised whole-blood NAD+ by 22%, 51% and 142% respectively — a textbook dose-dependent rise, maintained throughout the study, with no flushing and no significant adverse-event difference from placebo [4]. NR did not elevate LDL cholesterol or disrupt one-carbon metabolism [4]. It has also been tested in patient populations: in congestive heart failure, NR at 1000 mg twice daily for 21 days roughly doubled whole-blood NAD+ and reduced pro-inflammatory cytokine production in blood cells, and was well tolerated [7]. In Parkinson's disease, oral NR at 1000 mg/day for 30 days raised cerebral NAD+ measured by 31P-MRS and shifted the cerebrospinal-fluid metabolome [6]. The pattern is consistent: NR gets NAD+ up, safely, in healthy and sick people alike. What it reliably fixes clinically is still being worked out.
Nicotinamide Mononucleotide (NMN), the Step-Before-NAD+ Precursor
Nicotinamide mononucleotide (NMN) sits one biochemical step from NAD+, and it has its own stack of randomized trials. A multicenter, double-blind, placebo-controlled, dose-ranging study in healthy middle-aged adults gave NMN at 300, 600 or 900 mg/day for 60 days; blood NAD+ rose significantly at days 30 and 60 across all NMN groups versus placebo (p ≤ 0.001), walking distance improved, a biological-age measure did not increase, and 600 mg/day was identified as the optimal dose with no safety issues at any dose [3]. A separate trial found 250 mg/day for 12 weeks significantly and persistently raised blood NAD+ in healthy subjects with no safety signals, and levels returned to baseline by 16 weeks after stopping — confirming the effect is real and reversible [9]. In healthy older men, 250 mg/day for 12 weeks raised NAD+ metabolites and produced statistically significant gains in gait speed (p=0.033) and left-hand grip strength (p=0.019), though muscle mass was unchanged [10]. And in prediabetic postmenopausal women, 250 mg/day for 10 weeks improved muscle insulin sensitivity by a hyperinsulinemic-euglycemic clamp, with no change in body composition or HbA1c [1]. Note the regulatory asterisk: NMN's status as a dietary supplement is contested by the FDA — a marketplace dispute, covered on the safety page, not a ban.
What moved, what stayed mixed, and what nobody has shown
Moved, reliably (RCT-confirmed): whole-blood NAD+, up and dose-dependently, with both NR [4] and NMN [3][9]. That is the strongest, most reproducible finding in the literature. Mixed: functional endpoints. Some trials report real gains — gait speed and grip strength in older men [10], muscle insulin sensitivity in prediabetic women [1], walking distance with NMN [3] — but these are modest, population-specific and not uniformly replicated. Not shown: hard clinical outcomes in humans. A 2025 Nature Metabolism review of NAD+ precursor supplementation in human ageing concluded that human trials have demonstrated limited efficacy, that age-related NAD+ decline has been consistently observed in only a limited number of human studies, and that tissue-specific NAD+ data remain sparse — calling for more clinical study rather than reliance on rodent extrapolation [15]. "Blood NAD+ went up" is true and well-documented. "NAD+ reverses aging" is not something the dealt trials demonstrate.
Is taking NAD orally effective?
For raising blood NAD+, yes — but via precursors, not NAD+ itself. Randomized trials show oral NMN and NR reliably raise blood NAD+ (NR by 22%/51%/142% at 100/300/1000 mg/day) [4]. Functional endpoints like muscle function or walking distance are more mixed, and a 2025 review concluded human efficacy for hard endpoints is still preliminary [15].
Is NAD+ shot worth it?
The controlled evidence does not support an NAD+ shot the way it supports oral precursors. Reviews note infused NAD+ is rapidly cleared from plasma, and the strongest randomized human data are for oral NMN and NR raising blood NAD+, not for injections or infusions [4][15]. This is research framing, not an endorsement, and no administration advice is given here.
Does NAD IV actually work?
Controlled efficacy data for IV NAD+ are limited. Reviews note infused NAD+ is rapidly cleared from plasma, so most of a dose does not persist [15]. The randomized human evidence that exists is overwhelmingly for oral NMN and NR raising blood NAD+ [3][4], not for IV infusions — covered further on the safety page.
Do NAD patches work?
Transdermal NAD+ or precursor patches are marketed with little controlled evidence. The randomized human data sit almost entirely on oral precursors (NMN, NR) [3][4]; no trial in the dealt evidence establishes that patches raise NAD+. Absent that data, claims for patches are not supported by what the studies here measured.